SCHEMBL2178242

SCHEMBL2178242

CC(C)[C@@H](C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(OC(F)(F)F)cc4)nn3)cc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.42
MAP3K5 Q99683 1/20 0.40
GCGR P47871 7/20 0.39
GIPR P48546 1/20 0.39
TRPV1 Q8NER1 1/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
NAMPT P43490 1/20 0.36
ABL1 P00519 2/20 0.36
MAPT P10636 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
SDCBP O00560 1/20 0.35
SDC2 P34741 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178251 1.00 THRB (0.42) THRBMAP3K5GCGRGIPRTRPV1
SCHEMBL2179418 0.88 ABL1 (0.42) THRBMAP3K5GCGRGIPRTRPV1
SCHEMBL2179427 0.88 ABL1 (0.42) THRBMAP3K5GCGRGIPRTRPV1
SCHEMBL2179464 0.88 THRB (0.43) THRBABL1
SCHEMBL2179162 0.88 MAP3K5 (0.42) THRBMAP3K5PSEN1PSEN2APH1B
SCHEMBL2178885 0.88 MAP3K5 (0.42) THRBMAP3K5PSEN1PSEN2APH1B
SCHEMBL2177379 0.85 THRB (0.52) THRBTRPV1LMNATP53NAMPT
SCHEMBL2179525 0.85 THRB (0.52) THRBTRPV1LMNATP53NAMPT
SCHEMBL2177299 0.82 MAP3K5 (0.40) MAP3K5TRPV1SDCBPSDC2
SCHEMBL2177305 0.82 MAP3K5 (0.40) MAP3K5TRPV1SDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT THRB 2612/4885MAP3K5 2168/4885GCGR 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.